Bone marrow transplantation for hemoglobinopathies

Current Opinion in Hematology

Volumn 7, Issue 2, 2000, Pages 95-100

  Mentzer, William C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARABINOSIDE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFEROXAMINE; LYMPHOCYTE ANTIBODY; METHOTREXATE;

ADULT; ARTICLE; BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; CHELATION; CHILD; GRAFT VERSUS HOST REACTION; HEMOGLOBINOPATHY; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON OVERLOAD; MAJOR CLINICAL STUDY; PHLEBOTOMY; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SURVIVAL RATE; THALASSEMIA;

ANEMIA, SICKLE CELL; BEHAVIOR THERAPY; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; HEMOGLOBINOPATHIES; HUMANS; THALASSEMIA; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033983027     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200003000-00004     Document Type: Article

References (35)

1. 1 Lucarelli G, Galimberti M, Giardini C, Polchi P, Angelucci E, Baronciani D, et al.: Bone marrow transplantation in thalassemia: the experience of Pesaro. Ann N Y Acad Sci 1998, 850:270-275. This report summarizes a 16-year experience with marrow transplantation for thalassemia in Pesaro, Italy.
2. 2 Lucarelli G, Clift RA, Galimberti M, Angelucci E, Giardini C, Baronciani D, et al.: Bone marrow transplantation in adult thalassemic patients. Blood 1999, 93:1164-1167. Older patients with thalassemia who are heavily iron-overloaded and who are not recuperating on conventional therapy may be respond positively to a modified conditioning regimen.
3. 3 Borgna-Pignatti C, Rugolotto S, De Stafano P, Piga A, Di Gregorio F, Gamberini MR, et al.: Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998, 850:227-231.
4. 4 Ghavamzadeh A, Nasseri P, Eshraghian MR, Jahani M, Baybordi I, Nateghi J, et al.: Prognostic factors in bone marrow transplantation for beta thalassemia major: experiences from Iran. Bone Marrow Transplant 1998, 22:1167-1169.
5. 5 Clift RA, Johnson FL: Marrow transplants for thalassemia: the USA experience. Bone Marrow Transplant 1997, 19(Suppl 2):57-59.
6. 6 Boulad F, Giardina P, Gillio A, Kernan N, Small T, Brochstein J, et al.: Bone marrow transplantation for homozygous β-thalassemia: the Memorial Sloan-Kettering Cancer Center experience. Ann N Y Acad Sci 1998, 850:498-502.
7. 7 Lee YS, Kristovich KM, Ducore JM, Vichinsky E, Crouse VL, Glader BE, et al.: Bone marrow transplantation in thalassemia: a role for radiation? Ann N Y Acad Sci 1998, 850:503-505.
8. 8 Mentzer WC, Cowan MJ: Bone marrow transplantation for β-thalassemia and hemoglobin E/β-thalassemia: the UCSF experience. J Pediatr Hematol Oncol, in press.
9. 9 Chik K, Shing MMK, Li CK, Leung TF, Tsang KS, Yuen HL, et al.: Treatment of hemoglobin Bart's hydrops with bone marrow transplantation. J Pediatr 1998, 132:1039-1042.
10. 10 Storb R, Yu C, Deeg HJ, Georges G, Kiem H-P, McSweeney PA, et al.: Current and future preparative regimens for bone marrow transplantation in thalassemia. Ann N Y Acad Sci 1998, 850:276-287.
11. 11 Piga A, Longo F, Voi V, Facello S, Miniero R, Dresow B: Late effects of bone marrow transplantation for thalassemia. Ann N Y Acad Sci 1998, 850:294-299. This is one of the few attempts to compare the risks and benefits of marrow transplantation with results of conventional transfusion and chelation in similar patient groups.
12. 12 Angelucci E, Muretto P, Lucarelli G, Ripalti M, Baronciani D, Erer B, et al.: Treatment of iron overload in the "ex-thalassemic." Ann N Y Acad Sci 1998, 850:288-293.
13. 13 Mariotti E, Angelucci E, Agostini A, Baronciani DB, Sgarbi E, Lucarelli G: Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br J Haematol 1998, 103:916-921.
14. 14 Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, et al.: Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Blood, in press. The largest reported experience with marrow transplantation for severely symptomatic sickle cell disease.
15. 15 Walters MC, Sullivan KM, Bernaudin F, Souillet G, Vannier J-P, Johnson FL, et al.: Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood 1995, 85:879-884.
16. 16 Abboud MR, Kletzel M, Miller S, Jackson S, Smith H, Laver J, et al.: Bone marrow transplantation for sickle cell disease [abstract]. Blood 1997, 90(Suppl 1):229.
17. 17 Abboud MR, Jackson SM, Barredo J, Holden KR, Cure J, Laver J: Neurologic complications following bone marrow transplantation for sickle cell disease. Bone Marrow Transplant 1996, 17:405-407.
18. 18 Bernaudin F, Souillet G, Vannier JP, et al.: Report of the French experience concerning 26 children transplanted for severe sickle cell disease. Bone Marrow Transplant 1997, 19:112-115.
19. 19 Vermylen C, Cornu G, Ferster A, et al.: Haemotopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998, 22:1-6. This is a study of a large series of patients, including 14 who had transplants in early stage disease before the onset of significant organ damage.
20. 20 Platt OS, Guínan EC: Bone marrow transplantation in sickle cell anemia:, the dilemma of choice. N Engl J Med 1996, 335:426-427.
21. 21 Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al.: Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998, 339:1565-1577.
22. 22 Kelly P, Kurtzberg J, Vichinsky E, Lubin B: Umbilical cord blood stem cells: application for the treatment of patients with hemoglobinopathies. J Pediatr 1997, 130:695-703.
23. 23 Miniero R, Rocha V, Saracco P, Locatelli F, Brichard B, Nagler A, et al.: Cord blood transplantation (CBT) in hemoglobinopathies. Bone Marrow Transplant 1998, 22(Suppl 1):78-79. Currently, this report reflects the largest experience with cord blood transplantion in hemoglobinopathies. A high rate of graft rejection was found.
24. 24 Sullivan KM, Anasetti C, Horowitz M, Rowlings PA, Petersdorf EW, Martin PJ, et al.: Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. Ann N Y Acad Sci 1998, 850:312-324.
25. 25 Werner E, Yanovich S, Rubinstein P, Kurtzberg J: Unrelated placental cord blood transplantation in a patient with sickle cell disease and acute non-lymphocytic leukemia [abstract]. Blood 1997, 90(Suppl 1):399.
26. 26 Flake AW, Zanjani ED: In utero transplantation for thalassemia. Ann N Y Acad Sci 1998, 850:300-311.
27. 27 Li CK, Yuen PMP, Wong R, Pang CP, Lai WK, Law E, et al.: Busulphan level and early mortality in thalassaemia patients after BMT. Bone Marrow Transplant 1999, 23:307-310.
28. 28 Poonkuzhali B, Srivastava A, Quernin MH, Dennison D, Aigrain EJ, Kanagasabapathy AS, et al.: Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1999, 24:5-11.
29. 29 Rosales F, Peylan-Ramu N, Civìdalli G, Varadi G, Or R, Naparstek E, et al.: The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases. Bone Marrow Transplant 1999, 23:861-865.
30. 30 Naparstek E, Delukina M, Or R, Nagler A, Kapelushnik J, Varadi G, et al.: Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies. Exp Hematol 1999, 27:1210-1218.
31. 31 Stewart FM, Zhong S, Wuu J, Hsieh C, Nilsson SK, Quesenberry PJ: Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood 1998, 91:3681-3687.
32. 32 Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763. Early experience with less toxic, nonmyeloablative conditioning regimen includes four subjects with nonmalignant diseases.
33. 33 Storb R, Yu C, Barnett T, Wagner JL, Deeg HJ, Nash RA, et al.: Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999, 94:1131-1136.
34. 34 Yu C, Nash R, Lothrop C, Zaucha J, Storb R: Severe canine hereditary hemolytic anemia treated by marrow grafts using nonmyeloablative immunosuppression [abstract]. Blood 1998, 92(Suppl 1):263.
35. 35 Niederwieser D, McSweeney P, Blume K, Storb R: Induction of complete or mixed chimerism using minimal conditioning and related or unrelated stem cell donors in patients with myeloid malignancies [abstract]. Ann Hematol 1999, 78(suppl 2):19.